摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-噻吩基氨基甲酸乙酯 | 105995-16-2

中文名称
2-噻吩基氨基甲酸乙酯
中文别名
2-噻吩-氨基甲酸乙酯
英文名称
ethyl thiophen-2-ylcarbamate
英文别名
ethyl 2-thienylcarbamate;[2]thienyl-carbamic acid ethyl ester;[2]Thienyl-carbamidsaeure-aethylester;2-Thienylcarbamic acid ethyl ester;ethyl N-thiophen-2-ylcarbamate
2-噻吩基氨基甲酸乙酯化学式
CAS
105995-16-2
化学式
C7H9NO2S
mdl
——
分子量
171.22
InChiKey
RRMXNBZSHDZAJJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    52 °C
  • 沸点:
    212.0±13.0 °C(Predicted)
  • 密度:
    1.269±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    11
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    66.6
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2934999090

SDS

SDS:0746ea3a261d135a0da8c170976d7a01
查看

反应信息

  • 作为反应物:
    描述:
    2-噻吩基氨基甲酸乙酯2-碘苯甲基溴 在 sodium hydride 作用下, 以 四氢呋喃 为溶剂, 反应 4.0h, 以70%的产率得到ethyl (2-iodobenzyl)(2-thienyl)carbamate
    参考文献:
    名称:
    Microwave-Assisted Intramolecular Cyclization of Electron-Rich Heterocycle Derivatives by a Palladium-Catalyzed Coupling Reaction
    摘要:
    通过微波辐照促进的分子内钯催化偶联反应,获得了氮化杂多环系统。
    DOI:
    10.1055/s-2007-990947
  • 作为产物:
    描述:
    2-噻吩甲酸乙醇氯化亚砜 、 sodium azide 、 十六烷基三甲基溴化铵 作用下, 以 二氯甲烷 为溶剂, 反应 27.0h, 以75%的产率得到2-噻吩基氨基甲酸乙酯
    参考文献:
    名称:
    Microwave-Assisted Intramolecular Cyclization of Electron-Rich Heterocycle Derivatives by a Palladium-Catalyzed Coupling Reaction
    摘要:
    通过微波辐照促进的分子内钯催化偶联反应,获得了氮化杂多环系统。
    DOI:
    10.1055/s-2007-990947
点击查看最新优质反应信息

文献信息

  • New and simple synthesis of acid azides, ureas and carbamates from carboxylic acids: application of peptide coupling agents EDC and HBTU
    作者:Vommina V. Sureshbabu、H. S. Lalithamba、N. Narendra、H. P. Hemantha
    DOI:10.1039/b920290k
    日期:——
    Conversion of carboxylic acids into acid azides using peptide coupling agents, EDC and HBTU is described. The procedure is efficient, practical and applicable to a diverse range of carboxylic acids including N-protected amino acids. Using the same reagents, one-pot synthesis of ureas, dipeptidyl urea esters and carbamates from acids has also been achieved.
    使用肽偶联剂,EDC和 HBTU描述。该程序高效,实用并且适用于多种羧酸,包括ñ保护的氨基酸。使用相同的试剂,还可以从酸一锅合成尿素,二肽基酯和氨基甲酸酯。
  • [EN] DIRECT PALLADIUM-CATALYZED AROMATIC FLUORINATION<br/>[FR] FLUORATION AROMATIQUE DIRECTE CATALYSÉE PAR DU PALLADIUM
    申请人:HARVARD COLLEGE
    公开号:WO2017156265A1
    公开(公告)日:2017-09-14
    Provided herein are palladium complexes comprising a ligand of Formula (Α') and a ligand of Formula (B), wherein R1-R18 are as defined herein. The palladium complexes are useful in methods of fluorinating aryl and heteroaryl substrates. Further provided are compositions and kits comprising the palladium complexes.
    本文提供了包含配体Α'的配合物和配体B的配合物,其中R1-R18如本文所定义。这些配合物可用于化芳基和杂环芳基底物的方法。此外,还提供了包含这些配合物的组合物和试剂盒。
  • Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections
    申请人:——
    公开号:US20040167096A1
    公开(公告)日:2004-08-26
    The present invention relates to novel compounds according to the to the general formulas I, II, III, IV or V: 1 wherein B is nucleoside base according to the structure: 2 R is H, F, Cl, Br, I, C 1 -C 4 alkyl (preferably CH 3 ), —C≡N, —C≡C—R a , 3 X is H, C 1 -C 4 alkyl (preferably, CH 3 ), F, Cl, Br or I; Z is O or CH 2 , with the proviso that Z is CH 2 and not O when the compound is according to general formula II, R 3 is —C≡C—H and R 2 is H or a phosphate, diphosphate, triphosphate or phosphotriester group; R 1 is H, an acyl group, a C 1 -C 20 alkyl or an ether group; R 2 is H, an acyl group, a C 1 -C 20 alkyl or ether group, a phosphate, diphosphate, triphosphate, phosphodiester group or a 4 group; Nu is a radical of a biologically active antiviral compound such that an amino group or hydroxyl group from said biologically active antiviral compound forms a phosphate, phosphoramidate, carbonate or urethane group with the adjacent moiety; R 8 is H, or a C 1 -C 20 alkyl or ether group, preferably a C 1 -C 12 alkyl group; k is 0-12, preferably, 0-2; R 3 is selected from a C 1 -C 4 alkyl (preferably, CH 3 ), —(CH 2 ) n —C≡C—R a , 5 R 3a and R 3b are independently selected from H, F, Cl, Br or I; R 4 and R 5 are independently selected from H, F, Cl, Br, I, OH, C 1 -C 4 alkyl (preferably, CH 3 ), —(CH 2 ) n —C≡C—R a , 6 with the proviso that R 4 and R 5 are not both H; R a is H, F, Cl, Br, I, or —C 1 -C 4 alkyl, preferably H or CH 3 ; Y is H, F, Cl, Br, I or —C 1 -C 4 alkyl, preferably H or CH 3 ; and n is 0, 1, 2, 3, 4 or 5, preferably 0, 1 or 2; and their anomers, pharmaceutically acceptable salts, solvates, or polymorphs thereof.
    本发明涉及符合一般式I、II、III、IV或V的新化合物:其中B是核苷酸碱基,如结构式2所示;R为H、F、Cl、Br、I、C1-C4烷基(优选为CH3)、—C≡N、—C≡C—Ra、3X为H、C1-C4烷基(优选为 )、F、Cl、Br或I;Z为O或CH2,但当化合物为一般式II时,Z为 而非O;R3为—C≡C—H,R2为H或磷酸酯、二磷酸酯三磷酸酯磷酸三酯基团;R1为H、酰基、C1-C20烷基或醚基;R2为H、酰基、C1-C20烷基或醚基、磷酸酯、二磷酸酯三磷酸酯磷酸二酯基团或a4基团;Nu为生物活性抗病毒化合物的基团,使得生物活性抗病毒化合物的基或羟基与相邻的基团形成磷酸酯、酰胺酸酯、碳酸酯或基团;R8为H或C1-C20烷基或醚基,优选为C1-C12烷基;k为0-12,优选为0-2;R3为选自C1-C4烷基(优选为 )、—( )n—C≡C—Ra、5R3a和R3b独立选自H、F、Cl、Br或I;R4和R5独立选自H、F、Cl、Br、I、OH、C1-C4烷基(优选为 )、—( )n—C≡C—Ra,但R4和R5不能同时为H;Ra为H、F、Cl、Br、I或—C1-C4烷基,优选为H或 ;Y为H、F、Cl、Br、I或—C1-C4烷基,优选为H或 ;n为0、1、2、3、4或5,优选为0、1或2;以及它们的异构体、药学上可接受的盐、溶剂或多晶体。
  • Are thiophenes attacked at sulphur by nitrenes?
    作者:Otto Meth-Cohn、Gerda van Vuuren
    DOI:10.1016/s0040-4039(86)80061-2
    日期:1986.1
    Ethyl azidoformate is shown to attack a range of thiophenes at sulphur giving transient S,N-ylides which can be trapped with acenaphthylene as [4+2] adducts; thiophene yields self-trapped products also.
    叠氮甲酸乙酯显示出在原子上攻击一系列噻吩,产生瞬时的S,N-烷基化物,可以将它们作为[4 + 2]加合物被with烯捕获;噻吩也可产生自陷产物。
  • [EN] NEW ANTI-MYCOBACTERIAL DRUGS AGAINST TUBERCULOSIS<br/>[FR] NOUVEAUX MÉDICAMENTS ANTI-MYCOBACTÉRIENS CONTRE LA TUBERCULOSE
    申请人:UNIV GEORGIA
    公开号:WO2013148174A1
    公开(公告)日:2013-10-03
    The present invention relates to the field of anti-mycobacterial therapeutics, in particular the treatment of tuberculosis, especially including pulmonary multidrug-resistant tuberculosis (MDR-TB), with applications in extensively drug-resistant tuberculosis (XDR-TB) and extremely drug-resistant tuberculosis (XXDR-TB), preferably in combination therapy.
    本发明涉及抗结核治疗领域,特别是肺部多药耐药结核病(MDR-TB)的治疗,包括广泛耐药结核病(XDR-TB)和极度耐药结核病(XXDR-TB),优选采用联合治疗。
查看更多